Selective oestrogen receptor modulators: A new paradigm for HRT

Current Opinion in Obstetrics and Gynecology

Volumn 10, Issue 3, 1998, Pages 189-192

  Baynes, Kevin C R ^a   Compston, Juliet E ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; RALOXIFENE;

BONE DENSITY; DRUG DESIGN; DRUG EFFECT; DRUG SYNTHESIS; ESTROGEN ACTIVITY; FEMALE; HORMONE RECEPTOR INTERACTION; HORMONE SUBSTITUTION; HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; RECEPTOR AFFINITY; REVIEW;

BREAST NEOPLASMS; ESTROGEN ANTAGONISTS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; PIPERIDINES; RALOXIFENE; RECEPTORS, ESTROGEN;

EID: 0031746101     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001703-199806000-00002     Document Type: Review

References (32)

1. Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA 1991; 265:1861-1867.
2. Stampfer MJ, Colditz GA, Willett WC, Manson JAE, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen therapy and cardiovascular disease: 10 year follow-up from the Nurses' Health Study. N Engl J Med 1991; 325:756-762.
3. Wolf PH, Madans JH, Finucane FF, Higgins M, Kleinman JC. Reduction of cardiovascular disease-related mortality among postmenopausal women who use hormones: evidence from a national cohort. Am J Obstet Gynecol 1991; 164:489-494.
4. Tang MX, Jacobs D, Stern Y, Marder K, Schofield K, Gurland R, et al. Effect of oestrogen during menopause on risk and age of onset of Alzheimer's disease. Lancet 1996; 348:429-432.
5. Kawas C, Resnick S, Morrison A, Brookmeyer R, Corrada M, Zonderman A, et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore longitudinal study of aging. Neurology 1997; 48:1517-1521.
6. Paganini-Hill A, Henderson VW. Estrogen deficiency and risk of Alzheimer's disease in women. Am J Epidemiol 1994; 140:256-261.
7. Resnick SM, Metter EJ, Zonderman AB. Estrogen replacement therapy and longitudinal decline in visual memory. Neurology 1997; 49:1491-1497.
8. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997; 350:1047-1059. An authoritative account of the relative risk of breast cancer in users of HRT.
9. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. New Engl J Med 1995; 332:1589-1593.
10. Lindsay R, MacLean A, Kraszewski A, Hart DM, Clark AC, Garwood J. Bone response to termination of oestrogen treatment. Lancet 1978; i:1325-1327.
11. Felson DT, Zhang Y, Hannan MT, Kiel DP, Wilson PWF, Anderson JJ. The effect of postmenopausal estrogen therapy on bone density in elderly women. New Engl J Med 1993; 329:1141-1146.
12. Kiel DP, Felson DT, Anderson JJ, Wilson PWF, Moskowitz MA. Hip fracture and the use of estrogens in postmenopausal women. New Engl J Med 1987; 317:1169-1174.
13. Beato M, Truss M, Chavez S. Control of transcription by steroid hormone receptors. Ann NY Acad Sci 1996; 784:93-123.
14. Yang NN, Venugopalan M, Hardikar S, Glasebrook A. Identification of an estrogen response element activated by metabolites of 17β-estradiol and raloxifene. Science 1996; 273:1222-1225.
15. Kuiper GGJM, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson J-A. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996; 93:5925-5930.
16. Kuiper GGJM, Carlsson B, Grandien K, Enmark E, Häggblad J, Nilsson S, Gustafsson J-Å. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology 1997; 138:863-870.
17. Onoe Y, Miyaura C, Ohta H, Nozawa S, Suda T. Expression of estrogen receptor beta in rat bone. Endocrinology 1997; 138:4509-4512.
18. Pettersson K, Grandien K, Kuiper GGJM, Gustafsson J-Å. Mouse estrogen receptor β forms estrogen response element-binding heterodimers with estrogen receptor α. Mol Endocrinol 1997; 11:1486-1496.
19. Paech K, Webb P, Kuiper GGJM, Nilsson S, Gustafsson J-Å, Kushner PJ, Scanlan TS. Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites. Science 1997; 277:1508-1510. A mechanistically interesting basic science paper using reporter gene constructs.
20. Lubahn DB, Moyer JS, Golding TS, Couse JF, Korach KS, Smithies O. Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. Proc Natl Acad Sci USA 1993; 90:11162-11166.
21. Pan LC, Ke HZ, Simmons HA, Crawford DT, Chidsey-Frink KL, McCurdy SP, et al. Estrogen receptor-alpha knockout (ERKO) mice lose trabecular and cortical bone following ovariectomy. J Bone Mineral Res 1997; 12 (suppl 1):S134.
22. Brzozowski AM, Pike ACW, Dauter Z, Hubbard RE, Bonn T, Engström O, et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997; 389:753-758. A structural biology paper elegantly showing distinct oestrogen receptor conformations with different ligands.
23. Grese TA, Sluka JP, Bryant HU, Cullinan GJ, Glasebrook AL, Jones CD, et al. Molecular determinants of tissue selectivity in estrogen receptor modulators. Proc Natl Acad Sci USA 1997; 94:14105-14110.
24. Evans G, Bryant HU, Magee D, Sato M, Turner RT. The effects of raloxifene on tibia histomorphometry in ovariectomised rats. Endocrinology 1994; 94:2283-2288.
25. Black LJ, Sato M, Rowley ER, Magee DE, Bekele A, Willimas DC, et al. Raloxifene (LY139481 HCL) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomised rats. J Clin Invest 1994; 93:63-69.
26. Bryant HU, Glasebrook AL, Yang NN, Sato M. A pharmacological review of raloxifene. J Bone Mineral Metabol 1996; 14:1-9.
27. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux A-C, Shah AS, Huster WJ, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations and uterine endometrium in postmenopausal women. New Engl J Med 1997; 337:1641-1647. A large prospective study of effects of raloxifene treatment over 2 years on different variables.
28. 3 and calcium to prevent hip fracture in elderly women. New Engl J Med 1992; 327:1637-1642.
29. Chapuy MC, Arlot ME, Delmas PD, Meunier PJ. Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ 1994; 308:1081-1082.
30. Cummings SR, Black DM, Vogt TM. Changes in BMD substantially underestimate the anti-fracture effects of alendronate and other antiresorptive drugs. J Bone Mineral Res 1996; 11 (suppl 1):S102.
31. Prelevic GM, Jacobs HS. New developments in postmenopausal hormone replacement therapy. Curr Opin Obstet Gynecol 1997; 9:207-212.
32. Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C. A controlled trial of raloxifene (LY139481) HCL: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Mineral Res 1996; 11:835-842.